Selected price target: $40, roughly 22% above the most recent close and just above the highest published analyst target near $39. Strongest bullish factors: accelerating revenue growth, a major second-quarter earnings beat, raised full-year guidance, improving profitability, and a cash-rich balance sheet.

PGNY is down -9.67% in Friday's regular session, following a sharp after-hours selloff on Thursday after the company reported Q2 2026 results. The Q2 earnings beat analyst estimates (EPS of $0.55 vs. $0.34 consensus; revenue of $350.5M), but forward guidance disappointed investors.

Adjusted EPS (Earnings Per Share) of $2.58 crushed the Wall Street consensus estimate of roughly $1.83–$1.87, representing a beat of approximately 38–41%. Total revenue reached $106.1 billion, up 7.3% year-over-year and well above the analyst forecast of around $100 billion.

UnitedHealth Group reported second quarter 2026 revenues of $112.0 billion. Adjusted earnings per share reached $6.38, significantly exceeding analyst expectations of approximately $4.85.

Reported Q2 2026 operating revenue of $49.8 billion, up 0.8% year over year. Diluted EPS reached $6.71 and adjusted diluted EPS hit $7.45, exceeding internal outlook.

Molina Healthcare shares surged approximately 19.7% in the last 30 days, closing at $241.56 on July 14, 2026, up from $201.87 on June 15, 2026. The rally was fueled by a major Illinois Medicaid contract win, multiple analyst price-target increases, and an index reclassification into the Russell 2500 Value Index.

ELV dropped -10.85% during Wednesday's session, tumbling from a prior close of $426.79 to approximately $380.49, as a premarket selloff triggered by Q2 2026 earnings extended into regular trading. The company reported adjusted EPS of $7.45, handily beating the $6.21 consensus, and revenue of $49.8B (+0.8% YoY) also exceeded estimates — but margin deterioration dominated investor reaction.

ALHC shares traded near $20.14 in mid-July 2026, roughly flat over the trailing 30 days, masking a dramatic rally from mid-May lows followed by a sharp selloff on whistleblower allegations. First-quarter 2026 earnings of $0.05 per share crushed consensus estimates by 400%, with revenue climbing 33.3% year-over-year to $1.24 billion and full-year guidance raised.

CVS Health shares have gained approximately 6.4% over the last 30 days, building on a broader quarterly rally of roughly 30.5%. The company's June 2026 launch of a comprehensive GLP-1 support program across its 9,000 pharmacies has drawn analyst upgrades and renewed investor attention.

UNH shares rose approximately 6.5% over the last 30 days, consolidating after a powerful rally that lifted the stock more than 50% from early April lows. The stock’s massive quarterly surge was fueled by a strong first-quarter earnings beat, raised full-year guidance, and a broader rotation into defensive healthcare names.

UnitedHealth Group Incorporated is a leading diversified health care company that operates through two primary segments: UnitedHealthcare, which provides health benefits and insurance services, and Optum, which offers health services, pharmacy benefit management, and data analytics solutions.

ELV stock surged +18% over the last 30 days, driven primarily by a strong Q1 2026 earnings beat and raised full-year guidance. Over the past quarter, the stock rose +10%, recovering from earlier Medicaid and Medicare pressures amid improving sector sentiment.

Analysts expect Q1 2026 revenue of approximately $94.98 billion, implying slight growth from $94.6 billion in Q1 2025. Consensus adjusted EPS estimate stands at $2.21, a 1.8% decline from $2.25 reported last year.

Shares of ALHC plunged 11.18% to $20.02 from the previous close of $22.54. The selloff followed first-quarter 2026 earnings, where revenue beat estimates at $1.235 billion but EPS missed at $0.05 versus $0.09 expected.

ELV stock surged +26% over the past 30 days, propelled by a strong Q1 2026 earnings beat and raised full-year guidance. Over the past quarter, shares rose +9% amid volatility, recovering from earlier Medicaid cost pressures and regulatory concerns.

UNH stock surged +37% over the past 30 days, primarily driven by a strong Q1 2026 earnings beat and raised full-year guidance. Over the past quarter, shares rose +30%, reflecting recovery from earlier lows amid easing medical cost pressures and positive sector sentiment.

CVS Health stock rose approximately +12% over the last 30 days, rebounding from late-March lows around $70 amid positive market sentiment and sector outperformance. Over the past quarter, shares gained +12%, supported by a strong Q4 2025 earnings beat despite intra-quarter volatility.

UNH stock price surged +30% over the past 30 days, driven by a strong Q1 2026 earnings beat and raised full-year profit guidance. Over the past quarter, the stock declined -1%, marked by high volatility including a sharp early-year drop followed by a partial recovery.

CVS shares surged approximately 7.30% in premarket trading on April 7, 2026, putting the stock near $78.62 versus the prior session close of $73.28. The primary catalyst is the CMS finalization of 2027 Medicare Advantage payment rates at a net average year-over-year increase of 2.48%, dramatically exceeding the 0.09% proposed in January 2026.

Humana shares are surging approximately +10% in premarket trading on April 7, 2026, pushing the stock toward the ~$200 range from a prior close of $182.65. The primary catalyst is the Centers for Medicare and Medicaid Services (CMS) finalizing a 2.48% net average increase in Medicare Advantage (MA) payment rates for 2027 — dramatically better than the near-flat 0.09% increase initially proposed in January 2026.